Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Change in Account Payables for 6 consecutive years, with $537526.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 150.84% to $537526.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146827.0 through Dec 2025, down 45.98% year-over-year, with the annual reading at $146827.0 for FY2025, 45.98% down from the prior year.
  • Change in Account Payables for Q4 2025 was $537526.0 at Inhibikase Therapeutics, up from -$2.0 million in the prior quarter.
  • The five-year high for Change in Account Payables was $911832.0 in Q2 2025, with the low at -$2.0 million in Q3 2025.
  • Average Change in Account Payables over 5 years is -$32765.2, with a median of $17331.5 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 2415.21% in 2024, while the deepest fall reached 1104.36% in 2024.
  • Over 5 years, Change in Account Payables stood at $535977.0 in 2021, then crashed by 30.98% to $369950.0 in 2022, then plummeted by 123.73% to -$87794.0 in 2023, then tumbled by 1104.36% to -$1.1 million in 2024, then skyrocketed by 150.84% to $537526.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $537526.0, -$2.0 million, and $911832.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.